ReviewGut and liver2019
IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis.
Review in Gut and liver, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 60 citations in OpenAlex.
- Demystifying the imaging diagnoses of sclerosing cholangitis.Abdominal radiology (New York) · 2026Review
- Article
- Surgical management of recurrent spinal hypertrophic pachymeningitis: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Clinical features, responses to therapy and prognosis of 107 patients with IgG4-related cholangitis: a retrospective study.BMC gastroenterology · 2026Observational
- Primary sclerosing cholangitis complicated with ulcerative colitis and double gene mutations of UGT1A1 and SLC25A13: a case report.Frontiers in medicine · 2026Article
- Sclerosing Cholangitis and Multiple Liver Abscesses in a Patient with Thymoma, Myasthenia Gravis, and Immune Deficiency (Good's Syndrome).The American journal of case reports · 2025Article
- IgG4-related cholangitis - distinguishing from other benign biliary strictures: clinical features, imaging, and response to treatment: a retrospective study.BMC gastroenterology · 2025Article
- Beyond cholangiocarcinoma: imaging features of mimicking pathologies in the biliary tract.Abdominal radiology (New York) · 2025Review
- A Preliminary Study on Clinical Characteristics of Patients With Autoimmune Liver Following Coronavirus Disease 2019.Journal of tropical medicine · 2025Article
- An atypical case of isolated immunoglobulin G4-related sclerosing cholangitis with a cholangiogram resembling primary sclerosing cholangitis.Clinical journal of gastroenterology · 2024Article
- Recombinant adeno-associated virus 8-mediated inhibition of microRNA let-7a ameliorates sclerosing cholangitis in a clinically relevant mouse model.World journal of gastroenterology · 2024Article
- Renal Manifestations of IgG4-Related Disease: A Concise Review.International journal of nephrology · 2024Review
- Post-COVID-19 cholangiopathy: Systematic review.World journal of methodology · 2023Article
- Bile Duct Lithiasis Mimicking a Perihilar Cholangiocarcinoma-An Endless Dilemma: A Case Report.Journal of clinical medicine · 2023Article
- Morphological aspects of small-duct cholangiopathies: A minireview.World journal of hepatology · 2023Review
- IgG4-related digestive diseases: diagnosis and treatment.Frontiers in immunology · 2023Review
- Epidemiology and updated management for autoimmune liver disease.Clinical and molecular hepatology · 2023Article
- Ulcerative colitis complicated by primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome: a case report and literature review.Frontiers in immunology · 2023Review
- A Case of Hepatic Immunoglobulin G4-Related Disease Presenting as an Inflammatory Pseudotumor and Sclerosing Cholangitis.Diagnostics (Basel, Switzerland) · 2022Article
- A novel serum metabolomic panel distinguishes IgG4-related sclerosing cholangitis from primary sclerosing cholangitis.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sclerosing cholangitis (SC) is defined as a condition with progressive stenosis and destruction of the bile ducts due to diffuse inflammation and fibrosis and currently includes three categories: primary sclerosing cholangitis (PSC), secondary cholangitis, and IgG4-related sclerosing cholangitis (IgG4-SC). SC categories share similar clinical features, such as cholestasis. Patients with SC present with cholestatic symptoms, including jaundice and pruritus, and blood tests reveal elevation of cholestatic enzymes. Cholangiography, endoscopic or magnetic, is inevitably required for making a diagnosis. Although the presentation of IgG4-SC and PSC are similar, the comorbidities, treatment response, and outcomes differ significantly, and therefore, it is strongly advisable to be familiar with these two diseases to make a correct diagnosis. Differentiation of cholangiocarcinoma from IgG4-SC and PSC is also extremely important. In this review, the clinical characteristics, comorbidities, treatment and outcomes of IgG4-SC and PSC will be outlined based on experience mainly from Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.